Streptococcal glycoprotein-induced tumour cell growth inhibition involves the modulation of a pertussis toxin-sensitive G protein.

por Yoshida, J., Takamura, S., Suzuki, S., Nishio, M.
Publicado 1996

Characterisation of a vindesine-resistant human small-cell lung cancer cell line.

por Ohta, S., Nishio, K., Kubo, S., Nishio, M., Ohmori, T., Takahashi, T., Saijo, N.
Publicado 1993

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer

por Horiike, A, Kudo, K, Miyauchi, E, Ohyanagi, F, Kasahara, K, Horai, T, Nishio, M
Publicado 2011

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients

por Nishio, M, Ohyanagi, F, Horiike, A, Ishikawa, Y, Satoh, Y, Okumura, S, Nakagawa, K, Nishio, K, Horai, T
Publicado 2005

A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)

por Kunitoh, H, Tamura, T, Shibata, T, Imai, M, Nishiwaki, Y, Nishio, M, Yokoyama, A, Watanabe, K, Noda, K, Saijo, N
Publicado 2009

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer

por Nishio, M, Horai, T, Horiike, A, Nokihara, H, Yamamoto, N, Takahashi, T, Murakami, H, Yamamoto, N, Koizumi, F, Nishio, K, Yusa, W, Koyama, N, Tamura, T
Publicado 2013

Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer

por Ohyanagi, F, Yamamoto, N, Horiike, A, Harada, H, Kozuka, T, Murakami, H, Gomi, K, Takahashi, T, Morota, M, Nishimura, T, Endo, M, Nakamura, Y, Tsuya, A, Horai, T, Nishio, M
Publicado 2009

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation...

por Garon, E.B., Reck, M., Nishio, K., Heymach, J.V., Nishio, M., Novello, S., Paz-Ares, L., Popat, S., Aix, S. Ponce, Graham, H., Butts, B.D., Visseren-Grul, C., Nakagawa, K.
Publicado 2023

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

por Takeuchi, K., Togashi, Y., Kamihara, Y., Fukuyama, T., Yoshioka, H., Inoue, A., Katsuki, H., Kiura, K., Nakagawa, K., Seto, T., Maemondo, M., Hida, T., Harada, M., Ohe, Y., Nogami, N., Yamamoto, N., Nishio, M., Tamura, T.
Publicado 2016

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer...

por Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y.H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., Yoshimoto, T., Takata, S., Tamura, T.
Publicado 2022

Interplanar coupling-dependent magnetoresistivity in high-purity layered metals

por Kikugawa, N., Goswami, P., Kiswandhi, A., Choi, E. S., Graf, D., Baumbach, R. E., Brooks, J. S., Sugii, K., Iida, Y., Nishio, M., Uji, S., Terashima, T., Rourke, P.M.C., Hussey, N. E., Takatsu, H., Yonezawa, S., Maeno, Y., Balicas, L.
Publicado 2016

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial

por Kubota, K., Sakai, H., Katakami, N., Nishio, M., Inoue, A., Okamoto, H., Isobe, H., Kunitoh, H., Takiguchi, Y., Kobayashi, K., Nakamura, Y., Ohmatsu, H., Sugawara, S., Minato, K., Fukuda, M., Yokoyama, A., Takeuchi, M., Michimae, H., Gemma, A., Kudoh, S.
Publicado 2015

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Can...

por Nokihara, H, Lu, S, Mok, T S K, Nakagawa, K, Yamamoto, N, Shi, Y K, Zhang, L, Soo, R A, Yang, J C, Sugawara, S, Nishio, M, Takahashi, T, Goto, K, Chang, J, Maemondo, M, Ichinose, Y, Cheng, Y, Lim, W T, Morita, S, Tamura, T
Publicado 2017

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients

por O’Byrne, K.J., Lee, K.H., Kim, S.-W., Park, K., Nishio, M., Sakai, H., Ohe, Y., Fukuhara, T., Kang, J.-H., Daga, H., Yu, C.-J., Hotta, K., Tanaka, H., Takeda, M., Yokoyama, T., Nathan, F.E., Lee, J.-S.
Publicado 2022